Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498587 | 0.87 | KMT2A (0.48) | PLA2G7THRBMAPTTP53MEN1 | |
| SCHEMBL2804576 | 0.84 | CYP2C9 (0.40) | MAPTTP53MEN1KMT2APTGDR2 | |
| SCHEMBL3456892 | 0.83 | PLA2G7 (0.49) | PLA2G7THRBHPGDKMT2APTGDR2 | |
| SCHEMBL3456435 | 0.82 | PLA2G7 (0.39) | PLA2G7HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL3456442 | 0.80 | PTGDR2 (0.43) | PLA2G7HPGDPTGDR2 | |
| SCHEMBL6353594 | 0.79 | PLA2G7 (0.41) | PLA2G7HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL14498596 | 0.79 | CXCR2 (0.37) | PLA2G7HPGDPTGDR2ALDH1A1LMNA | |
| SCHEMBL2807725 | 0.76 | CYP2C9 (0.55) | MAPTMEN1KMT2APTGDR2LMNA | |
| SCHEMBL3457127 | 0.75 | FABP3 (0.39) | PLA2G7MEN1KMT2APTGDR2CYP2C9 | |
| SCHEMBL3456446 | 0.75 | FEN1 (0.41) | PLA2G7TP53HPGDPTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | PLA2G7 2/4885THRB 3534/4885MAPT 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.